UCB Biopharma SRL

Official Statements

Score contribution: 100 — 2 supporting sources.

Score 1002 references

Featured Reference

“Early Access Programs can provide an ethical path for patients to access treatments before they have been authorized to be sold. UCB participates in national Early Access Programs in collaboration with governments where appropriate, which are tailored to specific circumstances and health systems.”

Sustainable AccessSource

“If urgency and unmet patient need is high, and UCB has a medicine in development which may be of benefit for patients, UCB has established an Early Access Program. The Access $+$ program provides access to our treatments through a standard mechanism which receives, reviews, and manages requests for access to our investigational products or products approved by at least one major regulatory body. UCB also participates in national Early Access Programs in collaboration with governments where appropriate, which are tailored to specific circumstances and health systems.”

EAP Related Articles from Sponsor

Score contribution: 80 — 4 supporting sources.

Score 804 references

Featured Reference

Equitable access to medicines | UCBOpens in new window

We therefore regularly adapt our Managed Access or Patient Support Programs to provide fast-paced access to patients; we work closely with healthcare systems and payers to price our medicines according to their value to people with severe diseases, the healthcare system and society and to ensure that patients can access them without undue financial burden; we build and pilot new business models and approaches to reach people in all communities – which face a multitude of barriers that hinder access to medicines.

UCB presents latest scientific research in epilepsy at American ...Source

Dravet syndrome: data include an analysis of the efficacy and safety of fenfluramine, an assessment of real-world evidence from a retrospective cohort study using a national pharmacy database and data from the European early access program assessing medication regimen adjustments in children aged 2 years and older and adults.

Key modelling data for UCB half-year results 2024 and reminders for ...Source

EU Early Access Program underway in several countries

CLINICAL STUDY REPORT SYNOPSIS: SP0994Source

Subjects who completed SP0994 and who were treated with LCM monotherapy had the option to enroll in SP1042, a long-term, open-label, follow-up study or EP0072, a Managed Access Program, following unblinding of SPo994 and approval of the respective follow-on program.

Active EAPs on ClinicalTrials.gov

Score contribution: 60 — 2 supporting sources.

Score 602 references

Featured Reference

Compassionate Use Program With Brivaracetam for the Treatment of Patients With EpilepsyOpens in new window

Conditions: Epilepsy

Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)Source

Conditions: Rheumatoid Arthritis

Past EAPs on ClinicalTrials.gov

Score contribution: 40 — 2 supporting sources.

Score 402 references

Featured Reference

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)Opens in new window

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)Source

Conditions: Crohn's Disease

Expanded Access Intelligence

Official Statements

Active EAPs on ClinicalTrials.gov

Past EAPs on ClinicalTrials.gov

Reagan-Udall Foundation Insights

Partner with Right2Hope